AKR1C3 and acute myeloid leukemia: Because a steroidal AKR1C inhibitor, medroxyprogesterone acetate (MPA), stimulates the differentiation and apoptosis of AML leukaemia cell lines, AKR1C3 could also be a target for treatment of AML.9–11